Compass Therapeutics opened lower at $0.82, compared with its previous close of $0.83. In the last trading session, the stock traded between $0.80 and $0.83. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Compass Therapeutics is now worth
$ 22.79
Resulting in a loss of
$ 77.21 (77.21%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 10 Analysts
Buy
80%
Hold
20%
Sell
0%
Markets Today
Today's Change
$-0.01 (-1.47%)
Day High
$0.83
Day Low
$0.80
Day Open
$0.82
Prev Close
$0.83
Volume
16,07,623
1W Return
5.68%
1M Return
-12.51%
3M Return
-62.90%
6M Return
-55.30%
1Y Return
-82.33%
Fundamentals
Market Cap ($ Mn)
147
PE Ratio
-
PB Ratio
2.60
PEG Ratio
-
ROE
-45.22%
ROCE
-47.00%
EPS (TTM)
$-0.15
Investment Returns
1 Week
5.68%
1 Month
-12.51%
3 Months
-62.90%
6 Months
-55.30%
9 Months
-87.30%
Financials
Quarterly
All values in $ Mn
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
0.0
Sep 26
Updates
10Nov
Compass Therapeutics Q3 loss widens; Wedbush cuts PT to $0.9
Compass Therapeutics reported a Q3 loss of $(0.15) per share, missing consensus estimates by 15.38%. Losses widened 87.5% YoY from $(0.08) in the prior year period. Wedbush analyst Robert Driscoll maintained a Neutral rating on the stock. Price target was lowered from $1 to $0.9 following the earnings report.
2 days ago
15Oct
Compass Therapeutics grants 200,000 stock options to new hire
Granted 200,000 non-qualified stock options to a new employee. Exercise price set at $0.86, equal to October 13, 2026 closing price. Options have a 10-year term with a four-year vesting schedule. Grant issued under 2025 Inducement Plan per Nasdaq Rule 5635(c)(4).
29 days ago
23Sep
Wedbush downgrades Compass Therapeutics to Neutral, cuts target to $1
Wedbush downgraded Compass Therapeutics from Outperform to Neutral. Price target reduced from $5 to $1 by analyst Robert Driscoll. Rating change reflects a cautious stance on the biotech firm.
1mo ago
6Aug
Compass Therapeutics Q2 Results: Net loss widens to $25.2 million
Compass Therapeutics reported a Q2 2026 net loss of $25.2 million, up from $19.9 million in the prior year, as R&D and G&A expenses rose significantly. The company maintains $180 million in cash, sufficient to fund operations into 2028, while advancing its lead oncology candidate tovecimig toward a potential BLA filing.
3mo ago
17Jul
Compass Therapeutics to present tovecimig data at ESMO Congress 2026
Compass Therapeutics announced that its abstract on tovecimig in advanced biliary tract cancer has been accepted for an oral presentation at the ESMO Congress 2026 in Madrid. The presentation will highlight results from the Phase 2/3 COMPANION-002 trial assessing tovecimig in combination with paclitaxel.
